Promotion of Glioblastoma Cell Motility by Enhancer of Zeste Homolog 2 (EZH2) Is Mediated by AXL Receptor Kinase

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Ott, Martina ^a,b   Litzenburger, Ulrike M ^a,b   Sahm, Felix ^a,b   Rauschenbach, Katharina J ^a,b   Tudoran, Ruxandra ^a,b   Hartmann, Christian ^a,b,c   Marquez, Victor E ^d   von Deimling, Andreas ^a,b   Wick, Wolfgang ^a,b   Platten, Michael ^a,b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXL KINASE; DNA; HISTONE; HISTONE H3; NESTIN; PROTEIN TYROSINE KINASE; TRANSCRIPTION FACTOR EZH2; TUBULIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA METHYLATION; GENE INDUCTION; GENE SILENCING; GLIOBLASTOMA; HISTONE METHYLATION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

CELL LINE, TUMOR; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GLIOBLASTOMA; GLIOMA; HUMANS; NEOPLASM INVASIVENESS; POLYCOMB REPRESSIVE COMPLEX 2; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84867509134     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047663     Document Type: Article

References (66)

1. Prezioso C, Orlando V, (2011) Polycomb proteins in mammalian cell differentiation and plasticity. FEBS Lett 585: 2067-2077.
2. Chase A, Cross NC, (2011) Aberrations of EZH2 in cancer. Clin Cancer Res 17: 2613-2618.
3. De Haan G, Gerrits A, (2007) Epigenetic control of hematopoietic stem cell aging the case of Ezh2. Ann N Y Acad Sci 1106: 233-239.
4. Chang CJ, Yang JY, Xia W, Chen CT, Xie X, et al. (2011) EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling. Cancer Cell 19: 86-100.
5. Tsang DP, Cheng AS, (2011) Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2. J Gastroenterol Hepatol 26: 19-27.
6. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, et al. (2010) Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 42: 722-726.
7. Nikoloski G, Langemeijer SM, Kuiper RP, Knops R, Massop M, et al. (2010) Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 42: 665-667.
8. Orzan F, Pellegatta S, Poliani PL, Pisati F, Caldera V, et al. (2011) Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells. Neuropathol Appl Neurobiol 37: 381-394.
9. Lee J, Son MJ, Woolard K, Donin NM, Li A, et al. (2008) Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 13: 69-80.
10. Suva ML, Riggi N, Janiszewska M, Radovanovic I, Provero P, et al. (2009) EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res 69: 9211-9218.
11. Abdouh M, Facchino S, Chatoo W, Balasingam V, Ferreira J, et al. (2009) BMI1 sustains human glioblastoma multiforme stem cell renewal. J Neurosci 29: 8884-8896.
12. Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, et al. (2008) Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 27: 7274-7284.
13. Min J, Zaslavsky A, Fedele G, McLaughlin SK, Reczek EE, et al. (2010) An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med 16: 286-294.
14. Wagener N, Holland D, Bulkescher J, Crnkovic-Mertens I, Hoppe-Seyler K, et al. (2008) The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells. Int J Cancer 123: 1545-1550.
15. Wu ZL, Zheng SS, Li ZM, Qiao YY, Aau MY, et al. (2010) Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression. Cell Death Differ 17: 801-810.
16. Lu C, Bonome T, Li Y, Kamat AA, Han LY, et al. (2007) Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res 67: 1757-1768.
17. Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, et al. (2010) Regulation of tumor angiogenesis by EZH2. Cancer Cell 18: 185-197.
18. McCabe MT, Brandes JC, Vertino PM, (2009) Cancer DNA methylation: molecular mechanisms and clinical implications. Clin Cancer Res 15: 3927-3937.
19. Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, et al. (2011) An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478: 197-203.
20. Lemke D, Pfenning PN, Sahm F, Klein AC, Kempf T, et al. (2012) Costimulatory Protein 4IgB7H3 Drives the Malignant Phenotype of Glioblastoma by Mediating Immune Escape and Invasiveness. Clin Cancer Res 18: 105-117.
21. Svendsen CN, ter Borg MG, Armstrong RJ, Rosser AE, Chandran S, et al. (1998) A new method for the rapid and long term growth of human neural precursor cells. J Neurosci Methods 85: 141-152.
22. Opitz CA, Litzenburger UM, Lutz C, Lanz TV, Tritschler I, et al. (2009) Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells. 27: 909-919.
23. Glazer RI, Knode MC, Tseng CK, Haines DR, Marquez VE, (1986) 3-Deazaneplanocin A: a new inhibitor of S-adenosylhomocysteine synthesis and its effects in human colon carcinoma cells. Biochem Pharmacol 35: 4523-4527.
24. Schmitt M, Pawlita M, (2009) High-throughput detection and multiplex identification of cell contaminations. Nucleic Acids Res 37: e119.
25. Opitz CA, Litzenburger UM, Opitz U, Sahm F, Ochs K, et al. (2011) The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells. PLoS One 6: e19823.
26. Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A (2009) Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol.
27. Bruna A, Darken RS, Rojo F, Ocana A, Penuelas S, et al. (2007) High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 11: 147-160.
28. Eberwine J, Yeh H, Miyashiro K, Cao Y, Nair S, et al. (1992) Analysis of gene expression in single live neurons. Proc Natl Acad Sci U S A 89: 3010-3014.
29. van der Vlag J, Otte AP, (1999) Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat Genet 23: 474-478.
30. Bommi PV, Dimri M, Sahasrabuddhe AA, Khandekar J, Dimri GP, (2010) The polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors. Cell Cycle 9: 2663-2673.
31. Jung JW, Lee S, Seo MS, Park SB, Kurtz A, et al. (2010) Histone deacetylase controls adult stem cell aging by balancing the expression of polycomb genes and jumonji domain containing 3. Cell Mol Life Sci 67: 1165-1176.
32. Pasini D, Hansen KH, Christensen J, Agger K, Cloos PA, et al. (2008) Coordinated regulation of transcriptional repression by the RBP2 H3K4 demethylase and Polycomb-Repressive Complex 2. Genes Dev 22: 1345-1355.
33. Bernstein BE, Humphrey EL, Erlich RL, Schneider R, Bouman P, et al. (2002) Methylation of histone H3 Lys 4 in coding regions of active genes. Proc Natl Acad Sci U S A 99: 8695-8700.
34. Avilla E, Guarino V, Visciano C, Liotti F, Svelto M, et al. (2011) Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer. Cancer Res 71: 1792-1804.
35. Li Y, Ye X, Tan C, Hongo JA, Zha J, et al. (2009) Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis. Oncogene 28: 3442-3455.
36. Liu R, Gong M, Li X, Zhou Y, Gao W, et al. (2010) Induction, regulation, and biologic function of Axl receptor tyrosine kinase in Kaposi sarcoma. Blood 116: 297-305.
37. Rankin EB, Fuh KC, Taylor TE, Krieg AJ, Musser M, et al. (2010) AXL is an essential factor and therapeutic target for metastatic ovarian cancer. Cancer Res 70: 7570-7579.
38. Song X, Wang H, Logsdon CD, Rashid A, Fleming JB, et al. (2011) Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. Cancer 117: 734-743.
39. Hutterer M, Knyazev P, Abate A, Reschke M, Maier H, et al. (2008) Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme. Clin Cancer Res 14: 130-138.
40. Staflin K, Zuchner T, Honeth G, Darabi A, Lundberg C, (2009) Identification of proteins involved in neural progenitor cell targeting of gliomas. BMC Cancer 9: 206.
41. Vajkoczy P, Knyazev P, Kunkel A, Capelle HH, Behrndt S, et al. (2006) Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proc Natl Acad Sci U S A 103: 5799-5804.
42. Ou WB, Corson JM, Flynn DL, Lu WP, Wise SC, et al. (2011) AXL regulates mesothelioma proliferation and invasiveness. Oncogene 30: 1643-1652.
43. Wick W, Weller M, Weiler M, Batchelor T, Yung AW, et al. (2011) Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro Oncol 13: 566-579.
44. Lee WP, Wen Y, Varnum B, Hung MC, (2002) Akt is required for Axl-Gas6 signaling to protect cells from E1A-mediated apoptosis. Oncogene 21: 329-336.
45. Tai KY, Shieh YS, Lee CS, Shiah SG, Wu CW, (2008) Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-kappaB and Brg-1. Oncogene 27: 4044-4055.
46. Gjerdrum C, Tiron C, Hoiby T, Stefansson I, Haugen H, et al. (2010) Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A 107: 1124-1129.
47. Holland SJ, Pan A, Franci C, Hu Y, Chang B, et al. (2010) R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res 70: 1544-1554.
48. Keating AK, Kim GK, Jones AE, Donson AM, Ware K, et al. (2010) Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity. Mol Cancer Ther 9: 1298-1307.
49. Ye X, Li Y, Stawicki S, Couto S, Eastham-Anderson J, et al. (2010) An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene 29: 5254-5264.
50. Zhang YX, Knyazev PG, Cheburkin YV, Sharma K, Knyazev YP, et al. (2008) AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Res 68: 1905-1915.
51. Vuoriluoto K, Haugen H, Kiviluoto S, Mpindi JP, Nevo J, et al. (2011) Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene 30: 1436-1448.
52. Herranz N, Pasini D, Diaz VM, Franci C, Gutierrez A, et al. (2008) Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription factor. Mol Cell Biol 28: 4772-4781.
53. Mudduluru G, Ceppi P, Kumarswamy R, Scagliotti GV, Papotti M, et al. (2011) Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer. Oncogene 30: 2888-2899.
54. Au SL, Wong CC, Lee JM, Fan DN, Tsang FH, et al. (2012) Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis. Hepatology 56: 622-631.
55. Cao Q, Mani RS, Ateeq B, Dhanasekaran SM, Asangani IA, et al. (2011) Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell 20: 187-199.
56. Tan J, Yang X, Zhuang L, Jiang X, Chen W, et al. (2007) Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 21: 1050-1063.
57. Miranda TB, Cortez CC, Yoo CB, Liang G, Abe M, et al. (2009) DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther 8: 1579-1588.
58. Fiskus W, Buckley K, Rao R, Mandawat A, Yang Y, et al. (2009) Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells. Cancer Biol Ther 8: 939-950.
59. Fiskus W, Pranpat M, Balasis M, Herger B, Rao R, et al. (2006) Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Mol Cancer Ther 5: 3096-3104.
60. Breton CV, Salam MT, Gilliland FD (2011) Heritability and role for the environment in DNA methylation in AXL receptor tyrosine kinase. Epigenetics 6.
61. Zheng S, Houseman EA, Morrison Z, Wrensch MR, Patoka JS, et al. (2011) DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression. Neuro Oncol 13: 280-289.
62. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, et al. (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 100: 11606-11611.
63. Shi B, Liang J, Yang X, Wang Y, Zhao Y, et al. (2007) Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol Cell Biol 27: 5105-5119.
64. Smits M, Nilsson J, Mir SE, van der Stoop PM, Hulleman E, et al. (2010) miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. Oncotarget 1: 710-720.
65. Mudduluru G, Allgayer H, (2008) The human receptor tyrosine kinase Axl gene-promoter characterization and regulation of constitutive expression by Sp1, Sp3 and CpG methylation. Biosci Rep 28: 161-176.
66. Mudduluru G, Leupold JH, Stroebel P, Allgayer H, (2010) PMA up-regulates the transcription of Axl by AP-1 transcription factor binding to TRE sequences via the MAPK cascade in leukaemia cells. Biol Cell 103: 21-33.